Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK31858 QTc Interval Study in Healthy Participants
NCT07915024Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HSK31858 in Non-cystic fibrosis bronchiectasis (NCFB) (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Changes of QTc interval at Day 28. Started Aug 2026; status: recruiting.
02
Drugs
HSK31858
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT07915024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915024.